aTYR PHARMA INC

aTyr Pharma Inc. has been granted an additional 180-day period by Nasdaq, until November 30, 2026, to regain compliance with the minimum bid price requirement of $1.00 per share. The company had initially received a deficiency notice for failing to meet this requirement. Nasdaq has confirmed that aTyr Pharma meets all other listing standards, and the company intends to cure the deficiency, possibly through a reverse stock split. Failure to comply by the new deadline could lead to the delisting of its common stock from The Nasdaq Capital Market.

aTyr Pharma reported a consolidated net loss of $(10.8) million, or $(0.11) per share, for the first quarter of 2026, an improvement from $(14.9) million, or $(0.17) per share, in the prior year period. This reduction was primarily driven by a significant decrease in research and development expenses. However, the company also announced the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for efzofitimod in Japan, a partnership that had generated $20.0 million in milestone payments. Additionally, aTyr Pharma is facing ongoing securities class action litigation, with its CFO recently added as a defendant.

aTyr Pharma announced its first quarter 2026 financial results and provided a corporate update, highlighting a clear path forward for efzofitimod in pulmonary sarcoidosis following a Type C meeting with the FDA. The company plans to submit an IND in June 2026 for a new Phase 3 study for efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis. Additionally, aTyr Pharma is on track to complete enrollment in its Phase 2 EFZO-CONNECT™ study for SSc-ILD in the first half of 2026. The company reported a net loss of $(10.8) million for the quarter, with $68.3 million in cash and investments.

aTyr Pharma announced its participation in two upcoming investor conferences in May and June 2026. The company will attend the RBC Capital Markets Global Healthcare Conference on May 20, 2026, for 1x1 investor meetings. Additionally, aTyr Pharma will participate in the Jefferies Global Healthcare Conference on June 4, 2026, where President and CEO Sanjay S. Shukla will deliver a fireside chat, and management will be available for one-on-one meetings. A webcast of the Jefferies event will be available on the company's website.

aTyr Pharma announced a clear path forward for its lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis, following feedback from a Type C meeting with the FDA. The company plans to submit an Investigational New Drug (IND) application in June 2026 for a new Phase 3 study. This study will focus on patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, utilizing FVC as the primary endpoint and KSQ-Lung as a key secondary endpoint, with an increased dosing frequency.